EP0901536B1 - Schallschutzeinrichtung für gleise - Google Patents

Schallschutzeinrichtung für gleise Download PDF

Info

Publication number
EP0901536B1
EP0901536B1 EP97922748A EP97922748A EP0901536B1 EP 0901536 B1 EP0901536 B1 EP 0901536B1 EP 97922748 A EP97922748 A EP 97922748A EP 97922748 A EP97922748 A EP 97922748A EP 0901536 B1 EP0901536 B1 EP 0901536B1
Authority
EP
European Patent Office
Prior art keywords
slab
sound
proofing device
carrying
portions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97922748A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0901536A1 (de
Inventor
Bernhard Neumann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gmundner Fertigteile GmbH and Co KG
Original Assignee
Gmundner Fertigteile GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT93496A external-priority patent/AT403809B/de
Priority claimed from AT0101596A external-priority patent/AT405426B/de
Application filed by Gmundner Fertigteile GmbH and Co KG filed Critical Gmundner Fertigteile GmbH and Co KG
Priority to SI9730491T priority Critical patent/SI0901536T1/xx
Publication of EP0901536A1 publication Critical patent/EP0901536A1/de
Application granted granted Critical
Publication of EP0901536B1 publication Critical patent/EP0901536B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01B—PERMANENT WAY; PERMANENT-WAY TOOLS; MACHINES FOR MAKING RAILWAYS OF ALL KINDS
    • E01B19/00—Protection of permanent way against development of dust or against the effect of wind, sun, frost, or corrosion; Means to reduce development of noise
    • E01B19/003—Means for reducing the development or propagation of noise

Definitions

  • the invention relates to a soundproofing device for tracks, on the rails the sound-absorbing plates mounted on the track, which have elastic profiles the rails are supported, the plates arranged between the rails Bridge the space between the rails in a self-supporting manner.
  • the invention further relates on sound absorbing panels for such a soundproofing device.
  • the plates arranged between the rails of the track consist of three layers or layers that extend over elastic profiles on the rail foot, Support the web and the underside of the head.
  • the upper layer consists of steel wire mesh, the edge of which is glued, welded or vulcanized into the profile.
  • the middle layer is designed as a sound absorption layer and consists of glass wool or rock wool. This sound absorption layer lies on the lower layer, which is designed as a perforated wall or grate and is supported in a recess in the profile in the region of the rail foot.
  • the plates are also arranged on the outside of the rail and angled upward at the ends in order to form a lateral soundproofing wall.
  • Such mineral wool panels have sufficient sound absorption at high frequencies, but have inadequate sound insulation at low frequencies.
  • Another disadvantage of this construction is that the walkable perforated wall made of steel wire mesh can become detached from its anchoring in the profiles at higher and repeated loads, so that the sound absorption layer underneath can be damaged.
  • the dust penetrating through the perforated wall can be deposited on the top of the sound absorption layer and thus the sound damping effect can deteriorate progressively.
  • a soundproofing device for tracks is known in which panels made of wood fiber concrete are arranged between the rails of the track, which rest on the sleepers of the track and laterally more elastic with an intermediate layer Lay strips on the rails. There is no unsupported storage of these plates.
  • the invention has for its object to provide a soundproofing device for tracks sound-absorbing panels to create a good sound absorption or damping over the entire frequency range essential for the sound level of rail traffic has, with a permanent mechanical Strength of the device should be guaranteed.
  • the soundproofing device initially mentioned type according to the invention solved in that the Plates consist of particles made of porous lightweight material, which are connected at certain points with a binder, and that the Slabs have embedded reinforcement and are uncovered are.
  • the above can Objectives are met well.
  • the particular of the wheels of a rail vehicle and from the rails Airborne sound is emitted from the surface of the panels
  • Pores of the particles are absorbed and can also fine spaces between the particles, leaving the structure through spaces or channels between the particles penetrate deeper into the plate to gradually complete there to be subdued. Due to the reinforcement of the slabs too ensures their accessibility.
  • the plates is advantageously provided that the top of the panels is textured, being even better Results can be achieved if the structuring is irregular is.
  • the top of the plates is preferably parallel to the rails extending ribs, whereby a structurally simple to manufacture results.
  • the ribs have a trapezoidal shape Have a cross-section, as this means that the angle falls Sound waves can be better absorbed.
  • the wall of the cavity resonators and their sound openings with a sound absorbing structure are provided, and / or if the wall of the cavity resonators and their tubular sound openings with a sound-absorbing layer are provided.
  • the cavities forming the cavities after are designed to be open at the bottom and with a lower plate are covered.
  • the cavity resonators forming cavities open downwards are trained and together with the track bed Form resonance cavity.
  • the damped resonance frequency of the cavity resonators within a frequency range from 150 to 1000 Hz, preferably is between 500 and 1000 Hz.
  • a special embodiment is also within the scope of the invention provided in which the installation and removal the one to be provided between the two rails of a track Plates can be done in a very simple way.
  • This embodiment of the soundproofing device is thereby characterized in that the one between the two rails
  • the track lying space is bridged with partial plates arranged in pairs is, each with at least one support rib in the Latch chambers of the rails engage, the partial plates each pair of plates on their mutually facing edges are supported on each other and in this case with each partial plate meandering along the edge facing the other partial plate alternating successive support sections and support sections are provided, wherein the support sections through by the Outgoing plate top and up to the other partial plate facing depressions are formed and under the supporting sections starting from the underside of the plate Indentations above are formed, which are complementary are formed to the depressions of the support sections, and the Supporting sections of a partial plate on the support sections of the other sub-plate and the support sections of the other sub-plate rest on the support sections of a partial plate.
  • Plate pairs can be used when the partial plates are unfolded simply put together, after which the partial panels are no problem leveling the pair of plates between the rails can be inserted, and it will also be the sub-panels Loads not pushed apart.
  • a preferred type of the latter embodiment which is characterized in that on those surfaces which the partial plates of a plate pair lie against each other, Projections and depressions shaped complementary to the projections, in which the projections snap into place for mutual Locking of the partial plates are provided, has the advantage that the cohesion of the partial plates of a plate pair also is secured over a very long period of time even when unfavorable Vibrations affect the sub-panels.
  • Such a crowning can be on one Partial plate by one, of which the other partial plate of the Plate pair facing edge outgoing surface section, the extending from the underside of the plate, and a subsequent surface section, which is the bottom approaching the plate are formed. If you want one such formation of the sub-plates additionally a latching it is advantageous if you train them to that down at the end edges of the support sections pointing projections and on the wings of the support sections complementary depressions are provided for these projections.
  • the domed wings are shaped according to a toothing, which up to for leveling the position of the partial plates of the respective plate pair a sliding movement or rolling movement of each other facing wings and supporting surfaces on each other and in the leveled position of these partial plates against one Movement of these partial plates to each other blocks.
  • Partial plates favorable geometry, if one provides that the partial plates on the mutually facing edges from the underside of the plate starting from the top to be rounded, whereby the radius of curvature is equal to or less than the distance between these edges and the rail side edges of the Is partial panels. It is also a simple assembly the partial plates of a plate pair advantageous, if one provides that the two partial plates of a pair of plates on the underside of the plate approximately along a straight line apart. However, if you want the highest possible load capacity of the plate pair, it is favorable if one provides that the two partial plates of a plate pair on the The underside of the plate should be meandering.
  • the reinforcement provided in the sub-slabs changes extends over the plate surface and into the support sections and engages in the support sections and in the support ribs. It is also cheap if you provide that between the on the support sections provided wings and on the support sections provided support surfaces an elastic and / or shock-absorbing insert or coating is provided.
  • a sound absorbing plate according to the invention is thereby characterized in that the plate is made of porous particles
  • Lightweight material is made, which is connected at certain points with a binder are that the plate on opposite edges with support ribs for engaging in the link chambers of rails, that the plate has an embedded surface reinforcement, and that in the plate cavity resonators with one Large area of the plate directed tubular sound openings, whose cross section is significantly smaller than the cross section of the cavity resonators, are formed, which large area to form the top is provided when installing the plate in the track.
  • Hiebei is it is advantageous if those forming the cavity resonators Cavities to the large area that the tubular Side of the plate facing away from the sound openings, expanding are openly trained.
  • Embodiments of a plate designed according to the invention which for the aforementioned Training with partial plates to be assembled into a pair of plates are provided, are characterized in that the Plate consists of particles made of porous lightweight material, which with a binder are put together so that the plate is an embedded Reinforcement has that the plate on one edge side with a support rib for engaging in the tab chambers of Rails is provided and on the opposite of this support rib Edge side in meandering succession of supporting sections and has support portions, the support portions by starting from the top of the plate and up to the edge reaching depressions are formed and under the support sections starting from the underside of the plate, facing upwards Depressions are formed, which are complementary to the Depressions of the support sections are shaped.
  • the plate cavity resonators with a large area of the plate directed tubular sound openings are formed, which large area to form the Top is provided when installing the plate in the track. It is further advantageous if the provided in the plate Reinforcement extends over the entire slab area and in the support sections and in the support sections and in the Rib is enough. If desired, the plates or partial plates also with a preferably running along the edge made of metal or fiber-reinforced plastic, Frame.
  • the generally rectangular Plates 3 have the rails 2 along both of them extending edges projecting support ribs 4, which with the interposition of elastic profiles 5, e.g. made of rubber or elastomer, on the rail base 6, on the rail web 7 and on the Support the underside of the rail head 8 of the rails 2.
  • a lightweight material used for example plastic granules, granular or spherical and fired alumina particles, granular slag particles, or similar burned natural or artificial manufactured materials
  • these particles with a suitable Plastic binders or cement are connected at certain points, so that small gaps or channels 10 remain, one Air shutter pipe and a drain of penetrating rain or Allow melt water.
  • the one on the plates 3 impinging airborne sound is on the surface of the plates 3 absorbed by the pores of the particles 9 and can via the gaps or channels remaining between the particles 9 10 penetrate deeper into the plate 3 to gradually be absorbed there to become.
  • the surface of the plates 3 by structuring be enlarged.
  • the top 12 of the Plates 3 with parallel to the rails 2 and in Spaced ribs 13 may be provided, which, as shown in Figure 3, a trapezoidal cross-section and have a height a above the rail head 8, which is a permissible Value of e.g. Not exceed 5 cm.
  • the structuring can also be irregular, e.g. the distance of the Ribs 13 increases or decreases relative to each other.
  • the Top 12 can also, for example, truncated cones, truncated pyramids, Cylinders, cuboids, etc. can be provided either in the same or at different distances from each other are.
  • the tubular sound openings 15 are provided on the top 12 of the plates 3.
  • the cavity resonators 14 forming cavities frusto-conical and down formed open, the openings thus formed through one, e.g. glued to the plate 3, sub-plate 16 covered are to form the cavity resonator 14.
  • the cavities forming the cavity resonators left open at the bottom so that it can be the only shown schematically with a dash-dotted line Track bed 17 (e.g.
  • the cavities forming cavities 14 can also be of the Conical shape different, e.g. spherical, cylindrical, pyramid-shaped, etc. to be different To achieve frequency behavior in sound absorption.
  • the volumes of the cavity resonators 14 and Dimensions of the tubular sound openings can be varied in order the desired frequency response or frequency absorption spectrum to achieve.
  • the tubular sound openings 15 open, as shown in Figure 2, perpendicular to the top 12 of the plate 3. In a variation of this arrangement, the tubular sound openings 15 also open at an angle to the top 12 of the plates 3, to better absorb oblique sound waves.
  • the manufacture of the plates 3 with the cavity resonators 14 can be done in a rectangular shape, in the positive shapes the cavity resonators with attached pipe pieces for the sound openings are used, whereupon the shape with the Particle 9 and a binder filled and after curing of the binder is removed from the mold.
  • too prefabricated cavity resonators with attached pipe sections can be used as a sound opening in the form, either consist of a suitable sound absorbing material or provided with a layer of sound-absorbing material on the inside are.
  • the rails 2 can also on the outside of the rail the rails 2 sound absorbing plates with cavity resonators be provided.
  • the one on the right rail 2 Plate 18 shown with a dash-dotted line is on one End, similar to the plate 3 lying between rails 2 the rail 2 via an elastic profile 5 and at the other end supported by an elastic strip 19 and by means of a Fastening element, in particular a screw 20, fixed.
  • the one on the left rail 2, also with dash-dotted lines Plate 21 shown in line is the same as that Plate 18 supported and fixed, but has one on the outside end area bent at the top to create a soundproof wall form.
  • the two plates 18, 21 also have reinforcement (not shown) and, if necessary, structuring in the form of ribs (not shown). If desired, you can also use a plate that runs along the edge Frame.
  • a soundproofing device designed according to the invention the space between the two rails 2 of a track 1 22 with paired sound-absorbing partial plates 3a, 3b filled or bridged.
  • These partial plates 3a, 3b have Support ribs 4, which in the tab chambers 23 of the rails 2nd intervene, and there are between the support ribs 4 and Rails 2 elastic profiles 5 with an approximately C-shaped cross section inserted.
  • the partial plates 3a, 3b are included their support ribs 4 on the rail base 6 and laterally against the Rail web 7 supported and upwards by engagement under held the rail head 8.
  • Bridge the partial plates 3a, 3b the distance 24 between the rails 2 is self-supporting.
  • each of the partial plates 3a, 3b is provided with a plurality of supporting ribs 4, which are spaced from each other by the for the Rails 2 provided fasteners 25 accessible to let. But you can also choose a different plate size and panel mounting arrangement on each panel as well provide only one support rib 4.
  • each partial plate 3a and 3b along the the other partial plate 3b or 3a facing edge 15 or 16 meandering alternating successive support sections 28th and support sections 29 are provided, the support sections 28 through depressions 30 starting from the top 12 of the plate are formed, which face up to that of the other partial plate Reach the edge; under the support sections 29 are of the Plate underside 31 outgoing, upward, depressions 32 formed, and there are the support portions of the Sub-plate 3a on the support portions of sub-plate 3b and Supporting sections of the partial plate 3b on the support sections of the Partial plate 3a on; the depressions 30 are to the depressions 32 designed complementary, so that on the support sections 29 formed by the depressions 32 support surfaces 34 in substantially full on the through the depressions 30 on the Support sections 28 formed wings 33 rest.
  • the wings 33 provided in the support sections 28 have a cambered shape, and there is such a cambered Shape also in the support surfaces provided on the support sections 29 34 before, and it is due to this cambered form of the above Surfaces create a form cohesion of the partial plates 3a, 3b, which in the leveled position of the partial plates 3a, 3b a mutual movement of these partial plates in the direction the plate level (arrows 36) inhibits. Furthermore, are on the support surfaces 34 projections 37 and 33 wells on the wings 38, which are complementary to the projections 37, provided; in the leveled position of the partial plates, the Projections 37 into the recesses 38 so that there is a mutual locking of the partial plates 3a, 3b results.
  • an elastic and / or shock-braking effect Inlay or coating can be provided.
  • the wings 33 provided on the support sections extend from the edge 26 or 27 of the relevant sub-plate 3a or 3b starting, first steep away from the underside 31 of the plate rising and then flattening, what kind of joining the partial plates to the plate pairs is advantageous. Geometric seen it is favorable if such a domed shape Wings are shaped according to a toothing, which up to the leveled position of the partial plates 3a, 3b of the respective Plate pair a sliding movement or rolling movement of the wings and support surfaces facing each other enables, and in the leveled position (Fig. 5 to 7) locks these partial plates against movement to one another. This surface shape corresponding geometrically to a toothing can extend to the top of the plate 12.
  • the projections 37 can, as shown in FIGS. 5 to 8, provided on the end edges 39 of the support sections 29 be what brings advantages when joining the sub-panels may, but it is also possible to such projections 37 on others Position, e.g. slightly moved away from the edge of the support surfaces.
  • Both in the embodiment shown in Figures 5 to 7 as well as in the variant shown in Fig.10 are the two partial plates 3a, 3b of a plate pair on the Underside of plate 31 interlocking, so that the mutually facing edges of the partial plates 3a, 3b run along the underside of the plate following a meandering line 43. This results in a very close bond of the partial plates 3a, 3b forming a pair of plates.
  • FIGS. 11 to 16 are the partial plates 3a, 3b on the mutually facing edges 26, 27 starting from the underside of the plate 31 rounded upwards shaped, the radius of curvature of this rounding equal to or less than the distance 41 between the Edges 26, 27 and the rail-side edges 42 of the partial plates 3a, 3b. This measure is also possible for you uninhibited process of inserting the partial panels advantageous.
  • the reinforcement 11 provided in the sub-slabs over the whole surface extension of the partial plates 3a, 3b is sufficient and here, as indicated by the broken line in FIG. 8, both in the support sections 28 and in the support sections 29 as well as in the support ribs 4 engages.

Landscapes

  • Architecture (AREA)
  • Civil Engineering (AREA)
  • Structural Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Building Environments (AREA)
  • Soundproofing, Sound Blocking, And Sound Damping (AREA)
  • Railway Tracks (AREA)
  • Power-Operated Mechanisms For Wings (AREA)
  • Devices Affording Protection Of Roads Or Walls For Sound Insulation (AREA)
  • Signal Processing Not Specific To The Method Of Recording And Reproducing (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Magnetic Heads (AREA)
  • Noise Elimination (AREA)
  • Holo Graphy (AREA)
  • Bridges Or Land Bridges (AREA)
EP97922748A 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise Expired - Lifetime EP0901536B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI9730491T SI0901536T1 (en) 1996-05-29 1997-05-23 Track soundproofing arrangement

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AT93496A AT403809B (de) 1996-05-29 1996-05-29 Schallschutzeinrichtung für gleise
AT93496 1996-05-29
AT934/96 1996-05-29
AT0101596A AT405426B (de) 1996-06-11 1996-06-11 Schienengleiche eindeckung für gleise
AT101596 1996-06-11
AT1015/96 1996-06-11
PCT/AT1997/000109 WO1997045592A1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise

Publications (2)

Publication Number Publication Date
EP0901536A1 EP0901536A1 (de) 1999-03-17
EP0901536B1 true EP0901536B1 (de) 2002-12-11

Family

ID=25594370

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97922748A Expired - Lifetime EP0901536B1 (de) 1996-05-29 1997-05-23 Schallschutzeinrichtung für gleise

Country Status (14)

Country Link
US (1) US6253872B1 (2)
EP (1) EP0901536B1 (2)
JP (1) JP3822641B2 (2)
CN (1) CN100424268C (2)
AT (1) ATE229595T1 (2)
AU (1) AU738889B2 (2)
CA (1) CA2255946C (2)
DE (1) DE59708955D1 (2)
DK (1) DK0901536T3 (2)
ES (1) ES2186891T3 (2)
HU (1) HU221872B1 (2)
NO (1) NO316078B1 (2)
TW (1) TW345603B (2)
WO (1) WO1997045592A1 (2)

Families Citing this family (311)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19812481C2 (de) * 1998-03-21 2002-08-22 Johann Rath Vorrichtung zur Dämpfung von Schallemissionen an Gleisanlagen
DE29905550U1 (de) * 1999-03-26 2000-08-24 DVG Deutsche Verpackungsmittel GmbH, 90552 Röthenbach Absorptionsbelag zur Reduzierung der Schallabstrahlung für Gleiskörper
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US6481637B1 (en) * 2000-11-20 2002-11-19 Mcqueen Philip Jeffrey Rail pad and method for strain attentuation
DE10111919A1 (de) * 2001-03-13 2002-09-19 Boegl Max Bauunternehmung Gmbh Fahrwegträger
HU224236B1 (hu) * 2001-12-14 2005-06-28 Attila Szebeni Vasúti acélhidaknál alkalmazható, egymáshoz csatlakoztatott elemekbõl álló, zaj- és rezgéscsökkentett mûanyag járólemezrendszer
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
EP1517684B1 (en) 2002-06-27 2009-07-22 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
AT6414U1 (de) * 2002-07-17 2003-10-27 Gmundner Fertigteile Gmbh Gleisabdeckung
GB2399123B (en) * 2003-03-05 2006-03-01 Corus Uk Ltd Rail damper
US20040248877A1 (en) * 2003-04-30 2004-12-09 Sandeep Gupta Polycyclic diazodioxide-based Bcl-2 protein antagonists and use thereof
WO2004099158A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Monocyclic diazodioxide based bcl-2 protein antagonists
JP4847868B2 (ja) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US20100126797A1 (en) * 2004-02-12 2010-05-27 Humphries Eric C Panel Assembly For Traffic Noise Barrier Wall
US7546900B2 (en) * 2004-02-12 2009-06-16 Evonik Cyro Llc Panel assembly for traffic noise barrier wall
US8616331B2 (en) 2004-02-12 2013-12-31 Eric C. Humphries Panel assembly for traffic noise barrier wall
TWI347390B (en) * 2004-03-05 2011-08-21 Gmundner Fertigteile Gmbh Noise-reducing track cover
KR20070032700A (ko) 2004-05-20 2007-03-22 폴드알엑스 파마슈티칼스, 인크. 트랜스티레틴을 안정화하고 트랜스티레틴 미스폴딩을억제하기 위한, ２-((헤테로)아릴)-벤즈옥사졸 화합물 및유도체, 그리고 조성물 및 방법
EP1802303B1 (en) 2004-09-17 2011-11-02 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting a-synuclein toxicity
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
US20070131480A1 (en) * 2004-12-06 2007-06-14 Corbin Maxwell H Jr Sound arresting barrier
US7464791B2 (en) * 2005-01-27 2008-12-16 Pretty Products, Llc Acoustic mats and methods for making the same
US20060230699A1 (en) * 2005-03-22 2006-10-19 Keene James R Sound control flooring systems and methods therefor
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
AU2007225088B2 (en) * 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
CA2647543A1 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
AU2007260579B2 (en) * 2006-06-13 2012-09-06 Newstyle Nominees Pty Ltd Rail track crossing
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
PL2066662T3 (pl) 2006-09-21 2013-05-31 Kyorin Seiyaku Kk Inhibitory hydrolaz serynowych
JP2010507585A (ja) 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
JP5013590B2 (ja) * 2006-11-14 2012-08-29 エンデバーハウス株式会社 伸縮性に優れた線路用吸音材
US20080146605A1 (en) 2006-12-19 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
CA2671766A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
PT2144604E (pt) 2007-02-28 2011-10-19 Conatus Pharmaceuticals Inc Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
WO2008140859A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
EP2170062A4 (en) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
WO2009035634A2 (en) * 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
CN102344457B (zh) 2007-09-12 2015-07-22 杏林制药株式会社 作为 gsk-3 抑制剂的螺环状氨基喹诺酮
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
WO2009059512A1 (en) * 2007-11-07 2009-05-14 Wai Lun Ho Tunable vibration absorbing device
JP2011504485A (ja) * 2007-11-21 2011-02-10 ファーマクシス リミテッド Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
SI2947072T1 (sl) 2008-03-17 2017-03-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksikinazolin-4-iloksi)fenil)-3-(5-1,1,1-trifluoro-2- metilpropan-2-il)izoksazol-3-il)urea kot modulator raf kinaze pri zdravljenju rakavih bolezni
US20120034155A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
US8048204B2 (en) 2008-09-23 2011-11-01 Rwdi Air Inc. Wall assembly
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
AR075633A1 (es) 2009-02-27 2011-04-20 Ambit Biosciences Corp Compuestos moduladores de jak quinasa y sus metodos de uso
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
BRPI1008974A2 (pt) * 2009-03-11 2017-06-06 Kyorin Seiyaku Kk composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
US8146310B2 (en) * 2009-03-11 2012-04-03 Keene Building Products Co., Inc. Noise control flooring system
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
RU2539591C2 (ru) 2009-04-22 2015-01-20 Аксикин Фармасьютикалз, Инк. Антагонисты арилсульфонамида ccr3
KR101687144B1 (ko) 2009-04-22 2016-12-15 액시킨 파마수티컬스 인코포레이티드 2,5-이치환된 아릴설폰아마이드 ｃｃｒ3 길항제
EP2727908A3 (en) 2009-04-22 2014-08-20 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide CCR3 antagonists
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AU2010270605B2 (en) 2009-07-08 2014-07-31 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
EP2461811B1 (en) 2009-08-05 2016-04-20 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
JP2013502429A (ja) 2009-08-19 2013-01-24 アムビト ビオスシエンセス コルポラチオン ビアリール化合物及びその使用方法
NL2003697C2 (nl) * 2009-10-22 2011-04-26 Univ Twente Weg met geluid-diffractoren.
TW201120037A (en) 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US8528286B2 (en) * 2009-11-10 2013-09-10 Keene Building Products Co., Inc. Sound control mat
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
KR20120118008A (ko) 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
IN2012DN04858A (2) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
AU2011223873B2 (en) 2010-03-02 2015-06-25 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
EP2547655B1 (en) 2010-03-17 2016-03-09 Axikin Pharmaceuticals, Inc. Arylsulfonamide ccr3 antagonists
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
JP6019015B2 (ja) 2010-06-01 2016-11-02 ビオトヘルイク， インコーポレイテッド ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法
MX2012013879A (es) 2010-06-01 2013-04-03 Biotheryx Inc Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MX2012014273A (es) 2010-06-07 2013-03-22 Novomedix Llc Compuestos furanilo y su uso.
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
EP2611448A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
ES2579942T3 (es) 2010-09-01 2016-08-17 Ambit Biosciences Corporation Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma
EP2611793A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
WO2012030924A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US20130317045A1 (en) 2010-09-01 2013-11-28 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
EP2611794A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
CN103270030B (zh) 2010-09-01 2016-01-20 埃姆比特生物科学公司 吡唑基氨基喹唑啉的氢溴酸盐
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CN103298786B (zh) 2010-10-11 2016-01-20 埃克希金医药品有限公司 芳基磺酰胺盐ccr3拮抗剂
US20120125711A1 (en) * 2010-11-24 2012-05-24 Stahr Richard E Sound absorbing panel and system
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
WO2012106299A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
JP2014509648A (ja) 2011-03-28 2014-04-21 メイ プハルマ，インコーポレーテッド （α−置換シクロアルキルアミノ及びヘテロシクリルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、その医薬組成物、並びに増殖性疾患の治療におけるそれらの使用
WO2012135166A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
MX2013015373A (es) 2011-06-23 2014-02-11 Map Pharmaceuticals Inc Nuevos analogos de fluoroergolina.
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
RS54936B1 (sr) 2011-10-14 2016-11-30 Ambit Biosciences Corp Heterociklična jedinjenja i njihova upotreba kao modulatora receptora tirozin kinaza tipa iii
SG11201403434YA (en) 2011-12-19 2014-09-26 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
CA2859175A1 (en) 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
KR20140138293A (ko) 2012-03-16 2014-12-03 액시킨 파마수티컬스 인코포레이티드 3,5-다이아미노피라졸 키나아제 억제제
EP3438087A1 (en) 2012-05-02 2019-02-06 Boehringer Ingelheim International GmbH Substituted 3-haloallylamine inhibitors of ssao and uses thereof
EP3406598B1 (en) 2012-06-14 2020-01-29 Mayo Foundation for Medical Education and Research Pyrazole derivatives as inhibitors of stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
CN104781240A (zh) 2012-09-07 2015-07-15 埃克希金医药品有限公司 同位素富集的芳基磺酰胺ccr3拮抗剂
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
WO2014074765A2 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
CN104955801B (zh) 2012-11-30 2017-10-31 诺沃梅迪科斯有限公司 取代的二芳基磺酰胺及其用途
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
BR112015014964A2 (pt) 2012-12-21 2017-07-11 Map Pharmaceuticals Inc novos derivados de metisergida
CA2897665A1 (en) 2013-01-11 2014-07-17 Mayo Foundation For Medical Education And Research Vitamins c and k for treating polycystic diseases
SG11201509982UA (2) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
US9909269B2 (en) * 2013-07-07 2018-03-06 4Silence B.V. Diffractor for diffracting sound
KR20160055170A (ko) 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
KR102409739B1 (ko) 2014-03-20 2022-06-17 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
KR102416358B1 (ko) 2014-03-20 2022-07-07 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
ES2751652T3 (es) 2014-05-12 2020-04-01 Conatus Pharmaceuticals Inc Tratamiento con inhibidor de caspasa emricasan de las complicaciones por las enfermedades hepáticas crónicas
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
BR112017004708A2 (pt) 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
WO2016065264A1 (en) 2014-10-24 2016-04-28 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
JP7211703B2 (ja) 2014-12-22 2023-01-24 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
JP6856532B2 (ja) 2015-01-20 2021-04-07 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ エルゴリン化合物およびその使用
WO2016119700A1 (en) 2015-01-28 2016-08-04 Jn Therapeutics Substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
EA036837B1 (ru) 2015-06-23 2020-12-25 Нейрокрин Байосайенсиз, Инк. Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
MY193767A (en) 2015-10-30 2022-10-27 Neurocrine Biosciences Inc Valbenazine salts and polymorphs thereof
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
JP7011596B2 (ja) 2015-12-02 2022-02-10 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
JP2019500397A (ja) 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤を肝疾患の治療に使用する方法
EP3399981B1 (en) 2016-01-08 2023-08-02 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
CN108430473B (zh) 2016-01-08 2021-08-31 细胞基因公司 抗增殖化合物以及其药物组合物和用途
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10407437B2 (en) 2016-03-08 2019-09-10 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
EP3426301A4 (en) 2016-03-08 2019-11-06 Los Gatos Pharmaceuticals, Inc. VERBUNDNANOPARTICLES AND USES THEREOF
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
ES2939373T3 (es) 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
DE102016111064A1 (de) * 2016-06-16 2017-12-21 Vossloh-Werke Gmbh Elastisches Element für einen Befestigungspunkt für eine Schiene für Schienenfahrzeuge und Befestigungspunkt
CN106087611B (zh) * 2016-06-20 2019-07-12 勾厚渝 轨道交通构件
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
CN109982687A (zh) 2016-09-19 2019-07-05 梅制药公司 联合疗法
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018083538A1 (en) 2016-11-07 2018-05-11 Neuracle Scienc3 Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
TW201828932A (zh) 2016-11-09 2018-08-16 美商諾沃麥迪斯有限責任公司 1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
EP3548007A4 (en) 2016-12-01 2020-08-12 Ignyta, Inc. METHOD OF TREATMENT OF CANCER
TW202345829A (zh) 2016-12-02 2023-12-01 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
US10961276B2 (en) 2017-02-17 2021-03-30 CAMRIS International, Inc. Universal antivenom
KR102874295B1 (ko) 2017-02-17 2025-10-20 에이도스 테라퓨틱스, 인코포레이티드 Ag-10, 이의 중간체, 및 이의 염을 제조하는 방법
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
BR112019020185A2 (pt) 2017-03-27 2020-06-02 Celgene Corporation Métodos e composições para redução da imunogenicidade
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
JP7076059B2 (ja) 2017-06-27 2022-05-27 ニューラクル サイエンス カンパニー リミテッド 抗ｆａｍ１９ａ５抗体及びその用途
JP7012384B2 (ja) 2017-06-27 2022-02-14 ニューラクル サイエンス カンパニー リミテッド 癌治療のための抗ｆａｍ１９ａ５抗体の用途
EP3645039A4 (en) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
WO2019003162A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, MEMBER A5, FOR THE TREATMENT OF GLAUCOMA
AU2018324070B2 (en) 2017-09-01 2023-05-18 East Carolina University Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
ES3024958T3 (en) 2017-09-21 2025-06-05 Neurocrine Biosciences Inc High dosage valbenazine formulation and compositions, methods, and kits related thereto
US12072339B2 (en) 2017-10-02 2024-08-27 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment and diagnosis of mood disorders
WO2019071021A2 (en) 2017-10-04 2019-04-11 The Regents Of The University Of California IMMUNOMODULATORY OLIGOSACCHARIDES
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
JP7395480B2 (ja) 2018-01-10 2023-12-11 クラ セラピューティクス， エルエルシー フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
US11058668B2 (en) 2018-03-23 2021-07-13 Eidos Therapeutics, Inc. Methods of treating TTR amyloidosis using AG10
CA3097999A1 (en) 2018-04-24 2019-10-31 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
CA3098805A1 (en) 2018-05-10 2019-11-14 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
CN108533609B (zh) * 2018-06-27 2020-03-10 贵州筑信达创科技有限公司 导轨及滑动件的组合结构
CN108836091B (zh) * 2018-06-27 2020-12-04 贵州筑信达创科技有限公司 导轨
US11447497B2 (en) 2018-06-29 2022-09-20 Histogen, Inc. (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
IL325404A (en) 2018-08-17 2026-02-01 Eidos Therapeutics Inc Spice formulations containing 3-(3-(5,3-dimethyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid
WO2020070678A2 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
WO2020079595A1 (en) 2018-10-16 2020-04-23 Neuracle Science Co., Ltd. Use of anti-fam19a5 antibodies
EP3880231A1 (en) 2018-11-16 2021-09-22 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
WO2020118042A1 (en) 2018-12-05 2020-06-11 Jacobs Wagner Christine Borrelia burgdorferi peptidoglycan as a diagnostic and target for therapeutic intervention of lyme disease-related pathologies
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
JP7239216B2 (ja) 2018-12-27 2023-03-14 ニューラクル サイエンス カンパニー リミテッド 粥状硬化症を治療するための抗ｆａｍ１９ａ５抗体の使用
CA3117619A1 (en) 2019-01-02 2020-07-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
MA55080A (fr) 2019-02-26 2022-01-05 Inspirna Inc Anticorps anti-mertk à affinité élevée et utilisations associées
PL3935042T3 (pl) 2019-03-07 2024-11-04 Nobo Medicine Inc. Inhibitory kaspazy i sposoby ich zastosowania
EP3959292B1 (en) 2019-05-20 2025-07-02 NIRvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
US20220249707A1 (en) 2019-05-20 2022-08-11 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
CA3146159A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
EP3997068A1 (en) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
IL291345B2 (en) 2019-09-16 2024-04-01 Dice Alpha Inc Il-17a modulators and uses thereof
KR102337657B1 (ko) * 2019-11-06 2021-12-09 한국철도기술연구원 철도진동저감용 조립식 블록 및 이를 이용한 블록 구조물
IL294663A (en) 2020-01-13 2022-09-01 Neoimmunetech Inc Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
CN113136745B (zh) * 2020-01-17 2024-10-25 洛阳双瑞橡塑科技有限公司 一种轨道道床吸音减振装置
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
AU2021217373A1 (en) 2020-02-05 2022-08-04 Neoimmunetech, Inc. Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
US12006643B2 (en) * 2020-05-27 2024-06-11 Mute Wall Systems, Inc. Sound dampening barrier wall
WO2021242970A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
EP4168414A1 (en) 2020-06-18 2023-04-26 Shy Therapeutics LLC Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
JP7828905B2 (ja) 2020-06-30 2026-03-12 プロセッタ バイオサイエンシズ， インク． イソキノリン誘導体、合成の方法及びそれらの使用
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022094475A1 (en) 2020-11-02 2022-05-05 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
CA3195594A1 (en) 2020-11-05 2022-05-12 Byung Ha Lee Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
CN112712784B (zh) * 2020-11-30 2024-12-31 南京华秦光声科技有限责任公司 一种低频宽带平板吸声结构
TW202237580A (zh) 2020-12-14 2022-10-01 美商拜歐斯瑞克斯公司 Pde4降解劑、醫藥組合物及治療應用
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
EP4284377A1 (en) 2021-01-27 2023-12-06 Shy Therapeutics LLC Methods for the treatment of fibrotic disease
CR20230472A (es) 2021-03-10 2024-03-21 Dice Molecules Sv Inc Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
EP4326721A1 (en) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
WO2022251533A1 (en) 2021-05-27 2022-12-01 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
KR20240027676A (ko) 2021-06-02 2024-03-04 라이엘 이뮤노파마, 인크. Nr4a3-결핍 면역 세포 및 이의 용도
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
AU2022292649A1 (en) 2021-06-16 2024-01-04 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20240277857A1 (en) 2021-09-29 2024-08-22 Nbios, Inc. Coiled-coil fusion protein
US12017997B2 (en) 2021-10-22 2024-06-25 Prosetta Biosciences, Inc. Host-targeted pan-respiratory antiviral small molecule therapeutics
CA3237696A1 (en) 2021-11-08 2023-05-11 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
KR20240130705A (ko) 2021-12-30 2024-08-29 네오이뮨텍, 인코퍼레이티드 Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
EP4433040A4 (en) 2022-01-03 2025-11-12 Lilac Therapeutics Inc ACYCLIC THIOL PRODRUGS
AU2022441090A1 (en) 2022-02-17 2024-08-22 Novelty Nobility Inc. Antibody-drug conjugate.
JP2025507621A (ja) 2022-03-02 2025-03-21 ミトパワー， インク． ニコチン酸及びリボースから誘導体化した新規プロドラッグ
AR128918A1 (es) 2022-03-30 2024-06-26 Biomarin Pharm Inc Oligonucleótidos que omiten el exón 51 de distrofina y sus aplicaciones
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
WO2023201282A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
WO2023215781A1 (en) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
TW202413356A (zh) 2022-05-10 2024-04-01 美商拜歐斯瑞克斯公司 Ｃｄｋ蛋白降解劑、藥物組合物及其治療應用
KR20250027283A (ko) 2022-05-19 2025-02-25 라이엘 이뮤노파마, 인크. nr4a3을 표적하는 폴리뉴클레오타이드 및 이의 용도
CN120303264A (zh) 2022-09-09 2025-07-11 医诺康治疗公司 CK1α和双重CK1α/GSPT1降解化合物
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
US20240209100A1 (en) 2022-10-21 2024-06-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
WO2024092043A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
EP4608838A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
EP4608839A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
KR102870410B1 (ko) * 2022-12-09 2025-10-16 한국전자기술연구원 방음재 및 소음 제어 시스템
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
US20240383990A1 (en) 2023-04-07 2024-11-21 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
US20240368596A1 (en) 2023-05-05 2024-11-07 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
CN121263415A (zh) 2023-05-09 2026-01-02 普罗根托斯治疗公司 杂环化合物及其用途
CN121219320A (zh) 2023-05-19 2025-12-26 达科纳治疗有限公司 针对il12受体的双特异性激动性抗体
WO2025010272A1 (en) 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
US20250122182A1 (en) 2023-09-27 2025-04-17 Isosterix, Inc. MYST Inhibitors
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
AU2024366926A1 (en) 2023-10-23 2026-03-12 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators
WO2026080752A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. De novo antibodies to activin a receptor like type 1 (alk1)
WO2026080748A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Bone morphogenetic protein receptor type 2 (bmprii) antibodies
WO2026080757A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Activin receptor type ii a/b (actriia/b) antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991848A (en) * 1974-08-16 1976-11-16 Frigitemp Acoustical board
US4142468A (en) * 1976-04-20 1979-03-06 Charles Birnstiel Elevated rail transit guideway with noise attenuators
US4093120A (en) 1977-01-24 1978-06-06 Park Rubber Company Railroad crossing structure
DE7711191U1 (de) 1977-04-07 1978-09-28 Straetner Geb. Buss, Anita, 4300 Essen Fahrbahnplatte fuer schienengleiche bahnuebergaenge
DE2727644C2 (de) * 1977-06-20 1983-06-30 Gummiwerk Kraiburg Elastik Gmbh & Co, 8261 Tittmoning Schienengleicher Bahnübergang
DE3602313A1 (de) * 1986-01-27 1987-07-30 Clouth Gummiwerke Ag Schallabsorbierender laermschutz insbesondere fuer schotterlose gleise
DE3827547C2 (de) * 1988-08-13 2000-09-21 Zueblin Ag Schallabsorptionskonstruktion für schotterlose Eisenbahnoberbauten
US4960184A (en) * 1989-11-09 1990-10-02 Bruce Woodward Sound absorbing structure
DE4243102A1 (en) 1991-12-20 1993-07-01 Bold Karl Gmbh & Co Noise protection and sight wall with carrier girder construction
US5730548A (en) * 1994-02-11 1998-03-24 Autostrade-Concessioni E Costruzioni Autostrade S.P.A. Deadening road pavement and method for its realization
DE4414566C2 (de) * 1994-04-27 1997-11-20 Freudenberg Carl Fa Luftschalldämpfer
DE4417402A1 (de) 1994-05-18 1995-11-23 Gruenzweig & Hartmann Montage Schallschutzeinrichtung zur Schalldämpfung und -dämmung an Gleiskörpern
NL194553C (nl) 1994-06-06 2002-07-02 Veldhoen Raalte B V Inrichting voor de geluidsisolatie van een spoorbaan.
DE29515935U1 (de) * 1995-10-07 1995-11-30 Deutsche Asphalt GmbH, 63263 Neu-Isenburg Schallabsorber für einen schotterlosen Eisenbahnoberbau
IT1293307B1 (it) * 1997-07-09 1999-02-16 Dieselbox Sa Barriera antirumore a pannelli trasparenti,dotata di caratteristiche fonoisolanti e fonoassorbenti

Also Published As

Publication number Publication date
TW345603B (en) 1998-11-21
JP3822641B2 (ja) 2006-09-20
HUP9903612A3 (en) 2001-08-28
WO1997045592A1 (de) 1997-12-04
NO985600D0 (no) 1998-11-30
CA2255946C (en) 2006-03-14
NO316078B1 (no) 2003-12-08
US6253872B1 (en) 2001-07-03
JP2000510921A (ja) 2000-08-22
AU738889B2 (en) 2001-09-27
DE59708955D1 (de) 2003-01-23
EP0901536A1 (de) 1999-03-17
HU221872B1 (hu) 2003-02-28
DK0901536T3 (da) 2003-04-07
ES2186891T3 (es) 2003-05-16
NO985600L (no) 1998-11-30
ATE229595T1 (de) 2002-12-15
CA2255946A1 (en) 1997-12-04
CN1219989A (zh) 1999-06-16
AU2880197A (en) 1998-01-05
HUP9903612A2 (hu) 2000-02-28
CN100424268C (zh) 2008-10-08

Similar Documents

Publication Publication Date Title
EP0901536B1 (de) Schallschutzeinrichtung für gleise
EP0904461B1 (de) Schienengleiche eindeckung für gleise
DE2321676A1 (de) Schallschutzwand aus gummi-verbundwerkstoffen
EP0214524B1 (de) Mauerwerk- oder Pflasterstein aus Beton oder dergleichen
WO2013075159A1 (de) Lärmschutzvorrichtung
DE19620731A1 (de) Feste Fahrbahn für schienengebundene Fahrzeuge auf Brücken und Verfahren zu ihrer Herstellung
DE102007037339A1 (de) Gabionenkorb mit lärmdämmender, monolithischer Schicht aus Beton
DE4430769C2 (de) Eisenbahnoberbau mit einem auf einer durchgehenden Tragplatte aus Stahlbeton aufgelagerten Gleisrost
DE3827547C2 (de) Schallabsorptionskonstruktion für schotterlose Eisenbahnoberbauten
DE3134473A1 (de) Schotterloser oberbau fuer schienenbahnen
DE202011052057U1 (de) Lärmschutzvorrichtung
AT404147B (de) Schallschutzwand zur dämmung von schallemissionen von verkehrsmitteln
AT512523B1 (de) Fundamentlose Lärmschutzvorrichtung
DE19514458A1 (de) Schallabsorbierendes Wandelement
DE3544481A1 (de) Schallschutzwand und dafuer geeignetes wandelement
DE2937478A1 (de) Bauteilsatz und bauelement zur herstellung von bauwerken sowie damit gebildete mauer und verwendung zur mauerherstellung
AT500820B1 (de) Fahrschiene für einen schienentrog
DE3727947A1 (de) Schallabsorbierendes bauelement sowie verfahren zur herstellung desselben
AT403809B (de) Schallschutzeinrichtung für gleise
DE19540357C1 (de) Eisenbahnbrücke und Kulisse zur Schalldämpfung an dieser
DE19635788A1 (de) Schalldämpfungselement für Schienentrassen mit fester Fahrbahn
EP1136622B1 (de) Gleiseindeckung
AT512391B1 (de) Lärmschutzvorrichtung
EP0166719A2 (de) Profildichtung
DE29519169U1 (de) Vorrichtung zur Schalldämpfung einer festen Fahrbahn und damit ausgerüstete feste Fahrbahn

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT CH DE DK ES FI FR GB IT LI LU PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 981130

17Q First examination report despatched

Effective date: 20000830

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT CH DE DK ES FI FR GB IT LI LU PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 19981130

REF Corresponds to:

Ref document number: 229595

Country of ref document: AT

Date of ref document: 20021215

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 59708955

Country of ref document: DE

Date of ref document: 20030123

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20030329

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2186891

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030912

REG Reference to a national code

Ref country code: SI

Ref legal event code: IF

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: GMUNDNER FERTIGTEILE GESELLSCHAFT M.B.H. & CO. KG

Free format text: GMUNDNER FERTIGTEILE GESELLSCHAFT M.B.H. & CO. KG.#KUFERZEILE 30-32#A-4810 GMUNDEN (AT) -TRANSFER TO- GMUNDNER FERTIGTEILE GESELLSCHAFT M.B.H. & CO. KG.#KUFERZEILE 30-32#A-4810 GMUNDEN (AT)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20120529

Year of fee payment: 16

Ref country code: DK

Payment date: 20120522

Year of fee payment: 16

Ref country code: LU

Payment date: 20120530

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120529

Year of fee payment: 16

Ref country code: GB

Payment date: 20120425

Year of fee payment: 16

Ref country code: SE

Payment date: 20120518

Year of fee payment: 16

Ref country code: FI

Payment date: 20120523

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120516

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20120730

Year of fee payment: 16

Ref country code: ES

Payment date: 20120504

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20120427

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20120525

Year of fee payment: 16

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20131125

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 229595

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130531

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20130523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130524

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131125

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131203

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20130531

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 59708955

Country of ref document: DE

Effective date: 20131203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140131

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20140225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130531

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20140610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130523